ArticleCureus2025
When David Surrenders the Sling: The Misalignment of Science and Strategy in Biotech-Pharma Partnerships.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Partnerships between small biotechnology companies and large pharmaceutical corporations are essential to translating early discoveries into global therapies. Yet many of these alliances falter, not because of scientific failure, but because of structural, cultural, and ethical misalignment. What begins as a collaboration of complementary strengths often devolves into an unequal relationship, where the agility and innovation of the biotech are absorbed by the slower machinery of pharma. The result is stalled progress, diluted science, and lost opportunities for patients. This editorial examines the growing divide between small, platform-driven biotechs and large pharmaceutical partners, particularly as the frontier of medicine expands into digital, data-driven, and multimodal therapeutics. It explores how governance asymmetry, conflicting time horizons, and the commandeering of scientific authorship erode trust and value. Drawing on firsthand experience across multiple global collaborations, I argue that the future of medicine demands a new model of partnership, one that protects scientific sovereignty while enabling strategic alignment. True collaboration must evolve from transactional handoffs to the shared creation of enduring platforms that unite biology, behavior, and technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.